Recursion, a clinical stage drug development company based in Salt Lake City, has entered into an agreement to merge with Exscientia of London, England. Exscientia is an AI-based platform that enables design and development of small molecule drugs.
“Our mission at Recursion is to decode biology to radically improve lives. We are leading the industry by integrating technology to map and navigate biology and chemistry to achieve this ambitious aim,” said Chris Gibson, co-founder and CEO of Recursion. “Today, with the announcement of our proposed combination with Exscientia, we leap closer to our vision of a Please log in to see the rest of this story.
